Several examples have reached the clinical setting, such as those acting against the membrane protein TROP2, a cellular receptor involved in calcium signaling and linked to oncogenesis, in triple-negative breast cancer [10] or ErbB2 in HER2-positive breast cancer [8,11]. This evidence concerns the gene ERBB2 and breast carcinoma.